Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

An update at 7 years was conceived for our multicenter phase II study in which 55 elderly high-risk untreated diffuse large B-cell lymphoma patients were treated with (90)Y-ibritumomab tiuxetan after a short course of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefoni, V, Casadei, B, Bottelli, C, Gaidano, G, Ciochetto, C, Cabras, M G, Ansuinelli, M, Argnani, L, Broccoli, A, Gandolfi, L, Pellegrini, C, Zinzani, P L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916298/
https://www.ncbi.nlm.nih.gov/pubmed/27176801
http://dx.doi.org/10.1038/bcj.2016.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916298/
https://www.ncbi.nlm.nih.gov/pubmed/27176801
http://dx.doi.org/10.1038/bcj.2016.29

Ejemplares similares